MOST human acute myeloid leukaemia (AML) cells have limited proliferat
ive capacity, suggesting that the leukaemic clone may be maintained. b
y a rare population of stem cells(1-5). This putative leukaemic stem c
ell has not been characterized because the available in vitro assays c
an only detect progenitors with limited proliferative and replating po
tential(4-7). We have now identified an AML-initiating cell by transpl
antation into severe combined immune-deficient (SCID) mice. These cell
s homed to the bone marrow and proliferated extensively in response to
in vivo cytokine treatment, resulting in a pattern of dissemination a
nd leukaemic cell morphology similar to that seen in the original pati
ents. Limiting dilution analysis showed that the frequency of these le
ukaemia-initiating cells in the peripheral blood of AML patients was o
ne engraftment unit in 250,000 cells. We fractionated AML cells on the
basis of cell-surface-marker expression and found that the leukaemia-
initiating cells that could engraft SCID mice to produce large numbers
of colony-forming progenitors were CD34(+) CD38(-); however, the CD34
(+) CD38(+) and CD34(-) fractions contained no cells with these proper
ties. This in vivo model replicates many aspects of human AML and defi
nes a new leukaemia-initiating cell which is less mature than colony-f
orming cells.